1. Home
  2. BGLC vs HCWB Comparison

BGLC vs HCWB Comparison

Compare BGLC & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BGLC
  • HCWB
  • Stock Information
  • Founded
  • BGLC 2017
  • HCWB 2018
  • Country
  • BGLC Malaysia
  • HCWB United States
  • Employees
  • BGLC N/A
  • HCWB N/A
  • Industry
  • BGLC Medical Specialities
  • HCWB Biotechnology: Pharmaceutical Preparations
  • Sector
  • BGLC Health Care
  • HCWB Health Care
  • Exchange
  • BGLC Nasdaq
  • HCWB Nasdaq
  • Market Cap
  • BGLC 10.4M
  • HCWB 10.8M
  • IPO Year
  • BGLC N/A
  • HCWB 2021
  • Fundamental
  • Price
  • BGLC $5.58
  • HCWB $4.30
  • Analyst Decision
  • BGLC
  • HCWB Strong Buy
  • Analyst Count
  • BGLC 0
  • HCWB 1
  • Target Price
  • BGLC N/A
  • HCWB $35.00
  • AVG Volume (30 Days)
  • BGLC 176.1K
  • HCWB 5.8M
  • Earning Date
  • BGLC 11-14-2025
  • HCWB 11-13-2025
  • Dividend Yield
  • BGLC N/A
  • HCWB N/A
  • EPS Growth
  • BGLC N/A
  • HCWB N/A
  • EPS
  • BGLC N/A
  • HCWB N/A
  • Revenue
  • BGLC $9,551,559.00
  • HCWB $832,841.00
  • Revenue This Year
  • BGLC N/A
  • HCWB $178.36
  • Revenue Next Year
  • BGLC N/A
  • HCWB N/A
  • P/E Ratio
  • BGLC N/A
  • HCWB N/A
  • Revenue Growth
  • BGLC 4.01
  • HCWB N/A
  • 52 Week Low
  • BGLC $2.01
  • HCWB $2.77
  • 52 Week High
  • BGLC $15.60
  • HCWB $100.80
  • Technical
  • Relative Strength Index (RSI)
  • BGLC 53.85
  • HCWB 48.55
  • Support Level
  • BGLC $4.20
  • HCWB $4.05
  • Resistance Level
  • BGLC $6.00
  • HCWB $6.11
  • Average True Range (ATR)
  • BGLC 0.33
  • HCWB 0.50
  • MACD
  • BGLC 0.04
  • HCWB -0.02
  • Stochastic Oscillator
  • BGLC 76.76
  • HCWB 36.74

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

Share on Social Networks: